Lessons on responsiveness to adjuvant systemic therapies learned from the neoadjuvant setting

Breast

Volumn 18, Issue SUPPL.3, 2009, Pages

  Colleoni, Marco ^a   Viale, Giuseppe ^b   Goldhirsch, Aron ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Breast cancer; Neoadjuvant therapy; Predictive factors; Prognostic factors

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE DERIVATIVE; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER GRADING; CANCER REGRESSION; CELL PROLIFERATION; DISEASE FREE SURVIVAL; DRUG TARGETING; GENE OVEREXPRESSION; GENETIC ANALYSIS; HISTOPATHOLOGY; HORMONAL THERAPY; HUMAN; IMMUNOHISTOCHEMISTRY; MEDICAL DECISION MAKING; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PATIENT SELECTION; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROBABILITY; PROTEIN EXPRESSION; TREATMENT OUTCOME;

EID: 71749115087     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9776(09)70289-9     Document Type: Article

References (44)

1. Fisher B., Bryant J., Wolmark N., et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16 (1998) 2672-2685
2. Bear H.D., Anderson S., Brown A., et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21 (2003) 4165-4174
3. Rouzier R., Extra J.M., Klijanienko J., et al. Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol 20 (2002) 1304-1310
4. Scholl S.M., Pierga J.Y., Asselain B., et al. Breast tumour response to primary chemotherapy predicts local and distant control as well as survival. Eur J Cancer 31 (1995) 1969-1975
5. Kaufmann M., von Minckwitz G., Bear H.D., et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 18 (2007) 1927-1934
6. Ring A.E., Smith I.E., and Ashley S. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer 91 (2004) 1-6
7. Guarneri V., Broglio K., Kau S.W., et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 24 (2006) 1037-1044
8. Colleoni M., Viale G., Zahrieh D., et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res 10 (2004) 6622-6628
9. Goldhirsch A., Wood W.C., and Gelber R.D. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18 (2007) 1133-1144
10. Saphner T., Tormey D.C., and Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14 (1996) 2738-2746
11. Dowsett M., Harper-Wynne C., Boeddinghaus I., et al. HER2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res 61 (2001) 8452-8458
12. Dowsett M., and Dunbier A.K. Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin Cancer Res 14 (2008) 8019-8026
13. Sorlie T., Perou C.M., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98 (2001) 10869-10874
14. Colleoni M., Bagnardi V., Rotmensz N., et al. Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy. Breast Cancer Res Treat 116 (2009) 359-369
15. Cristofanilli M., Gonzalez-Angulo A., Sneige N., et al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol 23 (2005) 41-48
16. Cocquyt V.F., Blondeel P.N., Depypere H.T., et al. Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma. Eur J Surg Oncol 29 (2003) 361-367
17. Chaturvedi S., Heys S.D., Chaturvedi R.S., et al. Primary chemotherapy for breast cancers: does histological type of cancer matter?. Breast Cancer Res Treat 88 Suppl 1 (2004) S106 (abstract 2089).
18. Pu R.T., Schott A.F., Sturtz D.E., et al. Pathologic features of breast cancer associated with complete response to neoadjuvant chemotherapy: importance of tumor necrosis. Am J Surg Pathol 29 (2005) 354-358
19. Vincent-Salomon A., Pierga J.-Y., Gautier C., et al. Neoadjuvant chemotherapy for invasive lobular carcinoma of the breast: a poorer response rate but not a worse prognosis than invasive ductal carcinoma. Breast Cancer Res Treat 94 Suppl 1 (2005) S231 (abstract 5071).
20. Tubiana-Hulin M., Stevens D., Lasry S., et al. Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution. Ann Oncol 17 (2006) 1228-1233
21. Ellis M.J., Coop A., Singh B., et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19 (2001) 3808-3816
22. Smith I.E., Dowsett M., Ebbs S.R., et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 23 (2005) 5108-5116
23. Dowsett M., Ebbs S.R., Dixon J.M., et al. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer-astudy from the IMPACT trialists. J Clin Oncol 23 (2005) 2477-2492
24. Domagala W., Markiewski M., Harezga B., et al. Prognostic significance of tumor cell proliferation rate as determined by the MIB-1 antibody in breast carcinoma: its relationship with vimentin and p53 protein. Clin Cancer Res 2 (1996) 147-154
25. Mandard A.M., Denoux Y., Herlin P., et al. Prognostic value of DNA cytometry in 281 premenopausal patients with lymph node negative breast carcinoma randomized in a control trial: multivariate analysis with Ki-67 index, mitotic count, and microvessel density. Cancer 89 (2000) 1748-1757
26. de Azambuja E., Cardoso F., de Castro Jr. G., et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients. Br J Cancer 96 (2007) 1504-1513
27. Faneyte I.F., Schrama J.G., Peterse J.L., Remijnse P.L., Rodenhuis S., and van de Vijver M.J. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer 88 (2003) 406-412
28. Chang J., Ormerod M., Powles T.J., Allred D.C., Ashley S.E., and Dowsett M. Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer 89 (2000) 2145-2152
29. Petit T., Wilt M., Velten M., et al. Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase IIa status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer 40 (2004) 205-211
30. Colleoni M., Viale G., Zahrieh D., et al. Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy. Ann Oncol 19 (2008) 465-472
31. Ellis M.J., Tao Y., Luo J., et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 100 (2008) 1380-1388
32. Colleoni M., Bagnardi V., Rotmensz N., et al. A risk score to predict disease-free survival in patients not achieving a pathological complete remission after preoperative chemotherapy for breast cancer. Ann Oncol (2009) [Epub ahead of print].
33. Guarneri V., Broglio K., Kau S.W., et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 24 (2006) 1037-1044
34. Andre F., Mazouni C., Liedtke C., et al. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer. Breast Cancer Res Treat 108 (2008) 183-190
35. Gregory R.K., Powles T.J., Salter J., et al. Prognostic relevance of cerbB2 expression following neoadjuvant chemotherapy in patients in a randomised trial of neoadjuvant versus adjuvant chemoendocrine therapy. Breast Cancer Res Treat 59 (2000) 171-175
36. Rouzier R., Pusztai L., Delaloge S., et al. Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol 22 (2004) 2294-2302
37. Chollet P., Amat S., Belembaogo E., et al. Is Nottingham prognostic index useful after induction chemotherapy in operable breast cancer?. Br J Cancer 89 (2003) 1185-1191
38. Abrial S.C., Penault-Llorca F., Delva R., et al. High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer. Breast Cancer Res Treat 94 (2005) 255-263
39. Kaufmann M., von Minckwitz G., Smith R., et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol 21 (2003) 2600-2608
40. Paik S., Tang G., Shak S., et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor positive breast cancer. J Clin Oncol 24 (2006) 3726-3734
41. van't Veer L.J., Dai H., van de Vijver M.J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 (2002) 530-536
42. Kim C., Tang G., Baehner F., et al. A comparison of estrogen receptor (ER) measurement by three methods in node-negative, estrogen receptor (ER) positive breast cancer: ligand binding (LB), immunohistochemistry (IHC), and quantitative RT-PCR. Breast Cancer Res Treat 100 Suppl 1 (2006) S295 (abstract 3116).
43. Rouzier R., Perou C.M., Symmans W.F., et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11 (2005) 5678-5685
44. Gianni L., Zambetti M., and Clark K. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 23 (2005) 7265-7277